S100 Proteins: Novel Oxidant Scavengers In Allergic Inflammation
Funder
National Health and Medical Research Council
Funding Amount
$505,814.00
Summary
Allergic inflammation includes conditions such as dermatitis and asthma. Asthma, affects one in 10 adults and one in 6 Australians, costing ~$720 million/annum. We will characterize new mediators of oxidant defence which have suppressive effects on key pathogenic processes. The novel oxidative changes in S100 proteins may lead to new diagnostic reagents and new strategies for therapy. Results will open new frontiers in asthma biology and will apply to other chronic inflammatory diseases.
Characterisation Of The Host Response In A Mouse Model Of Staphylococcus Aureus Keratitis.
Funder
National Health and Medical Research Council
Funding Amount
$248,850.00
Summary
Staphylococcus is the most common cause of bacterial eye infections (microbial keratitis) . This ocular infection is associated with severe pain, redness, discharge and frequently results in the loss of vision or blindness. Predisposing factors for this disease include contact lens wear and immunocompromised individuals such as those with HIV, diabetes or aged populations. S. aureus keratitis is difficult to treat using conventional antibiotics as although bacteria may be eliminated, vision loss ....Staphylococcus is the most common cause of bacterial eye infections (microbial keratitis) . This ocular infection is associated with severe pain, redness, discharge and frequently results in the loss of vision or blindness. Predisposing factors for this disease include contact lens wear and immunocompromised individuals such as those with HIV, diabetes or aged populations. S. aureus keratitis is difficult to treat using conventional antibiotics as although bacteria may be eliminated, vision loss may still result from scarring. S. aureus also causes a wide range of hospital associated infections such as pneumonia, endocarditis, bacteremia, wound infections, osteomyelitis and septic arthritis. In recent times strains of S. aureus have emerged which are multi-drug resistant including methicillin resistant S. aureus (MRSA). These may only be treated with the drug Vancomycin. However, vancomycin resistant S. aureus have been reported in both Japan and the USA. Now, the search for new treatments for this bacterium is of vital importance. This project will utilise the novel S.aureus mouse model for keratitis, which we have developed in our laboratories. Our model will enable us to investigate the host responses to bacterial infection. Existing models in the rabbit do not allow such detailed studies due to the lack of existing molecular probes and antibodies. Insights into potential adjunct therapies will also be gained. This research could lead to the development of novel therapeutic measures aimed at manipulating the host response to reduce scarring and consequent blindness. This information may also be important for the development of prophylactic treatments for those patients at high risk, such as diabetics and immunocompromised individuals of developing this disease.Read moreRead less
Attenuated And Recombinant Mycobacterial Strains As Novel Vaccines To Control Tuberculosis
Funder
National Health and Medical Research Council
Funding Amount
$370,500.00
Summary
Tuberculosis is a major worldwide health problem. Around one third of the world s population is infected with the bacterium that causes tuberculosis, which results in 2 million deaths per year. Furthermore, people infected with the AIDS virus are at a much greater risk of catching tuberculosis. The only vaccine available for tuberculosis, known as BCG, is not very effective at preventing the disease. Therefore there is an urgent need to develop new vaccines to help combat tuberculosis. This proj ....Tuberculosis is a major worldwide health problem. Around one third of the world s population is infected with the bacterium that causes tuberculosis, which results in 2 million deaths per year. Furthermore, people infected with the AIDS virus are at a much greater risk of catching tuberculosis. The only vaccine available for tuberculosis, known as BCG, is not very effective at preventing the disease. Therefore there is an urgent need to develop new vaccines to help combat tuberculosis. This project aims to develop and test novel vaccines to prevent tuberculosis. We will produce forms of the existing BCG vaccine that have been altered to boost the components of the immune system needed to provide optimal protection against tuberculosis. Other potential vaccines that we will test are very similar to the bacterium that causes tuberculosis but have been altered such that they do not cause disease. Using animal models of tuberculosis and sophisticated immunological techniques we wish to determine if these live vaccines can stimulate the right type of immune response needed to fight tuberculosis and prevent infection. This is an internationally competitive project and our team is at the forefront of this research effort. A new, effective tuberculosis vaccine would be a major medical breakthrough and a represent a significant achievement for Australian health and medical research.Read moreRead less
Molecular Approaches To Developing Subunit Vaccines With Improved Efficacy Against Tuberculosis
Funder
National Health and Medical Research Council
Funding Amount
$480,750.00
Summary
Tuberculosis remains a major worldwide health problem, resulting in approximately 3 million deaths per year. Furthermore, people infected with the AIDS virus are at a much greater risk of catching tuberculosis. The only vaccine available for tuberculosis, known as BCG, is not very effective at preventing the disease. Therefore there is an urgent need to develop new vaccines to help combat tuberculosis. The bacterium that causes tuberculosis is made up of may proteins, some of which are known to ....Tuberculosis remains a major worldwide health problem, resulting in approximately 3 million deaths per year. Furthermore, people infected with the AIDS virus are at a much greater risk of catching tuberculosis. The only vaccine available for tuberculosis, known as BCG, is not very effective at preventing the disease. Therefore there is an urgent need to develop new vaccines to help combat tuberculosis. The bacterium that causes tuberculosis is made up of may proteins, some of which are known to induce immune responses in animals and humans. We will produce vaccines that are made from 13 of these important proteins. Using a laboratory animal model that closely mimics human tuberculosis infection, together with sophisticated immunological techniques, we will determine if these vaccines stimulate the right immune response to fight tuberculosis and prevent infection. In addition, we will exploit molecules known to boost immune responses to optimise these vaccines. Further we will study the recently sequenced genome of the tuberculosis bacterium to identify new proteins that may be included in these novel anti-tuberculosis vaccines. This is an internationally competitive project and our team is at the forefront of this research effort. A new, effective tuberculosis vaccine would be a major medical breakthrough and a represent a significant achievement for Australian health and medical research.Read moreRead less